TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2025.218187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Ting Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Membrane Proteins, Tumor Escape, Receptors, Interferon. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Sun Yat-sen University Cancer Center, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapies targeting the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis provide significant clinical benefits across multiple tumor types. Although interferon (IFN)-γ is essential for anti-tumor immunity, sustained IFN-γ signaling in the tumor microenvironment potently upregulates PD-L1 expression in tumor cells and induces profound T cell exhaustion, limiting the efficacy of ICB therapies. Therefore, further investigation into the regulation of IFN-γ-PD-L1 signaling is necessary for the development of more effective therapeutic strategies. Herein, transmembrane protein 199 (TMEM199) is identified as a novel regulator of IFN-γ-driven PD-L1 transcription. Mechanistically, TMEM199 and its important partner coiled-coil domain containing 115 (CCDC115) interact with IFNGR1/2 and facilitate their trafficking to RAB11A-positive recycling endosomes. TMEM199/CCDC115 also recruits transport protein particle (TRAPP) Ⅱ to the recycling endosomes and activates RAB11A, leading to enhanced IFNGR1/2 recycling and downstream PD-L1 upregulation. Collectively, these findings reveal that TMEM199 might be a promising therapeutic target for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR…
Förderung
- Sun Yat-sen University Cancer Center
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Li, T., Xie, M., Zhang, R., Zhong, J., Chen, Z., Lin, J., Zou, Y., Wu, Y., Kang, T., & Zhou, L. (2026). TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218187
Vancouver
Li T, Xie M, Zhang R, Zhong J, Chen Z, Lin J, et al. TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218187
BibTeX
@article{Li2026,
author = {Li, Ting and Xie, Miner and Zhang, Ruhua and Zhong, Jianliang and Chen, Zhenxuan and Lin, Jiahui and Zou, Yezi and Wu, Yuanzhong and Kang, Tiebang and Zhou, Liwen},
title = {TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2025.218187}
}
EUVIMED